Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients

다국어 초록 (Multilingual Abstract)

Tumor-induced osteomalacia (TIO) is a rare disease that manifests with paraneoplasic syndrome and overproduction of fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and hyperphosphaturia, eventually leading to acquired hypophosphatemic osteomalacia. Diagnosis of this disease is often challenging because of the small size of the lesion, which can be localized in bone or soft tissue anywhere in the body. Detecting these occult mesenchymal tumors (OMT) is of great importance as they are potentially curable after tumor resection. The purpose of this case series is to provide some insight into the diagnosis and localization of OMTassociated with osteomalacia, particularly using functional imaging with Ga68-DOTA peptide PET/CT scans.

참고문헌 (Reference)

1 Hu FK, "Tumorinduced osteomalacia with elevated fibroblast growth factor 23 : A case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature" 30 : 794-804, 2011

2 Jagtap VS, "Tumor-induced osteomalacia : a single center experience" 17 : 177-184, 2011

3 Chong WH, "Tumor-induced osteomalacia" 18 : R53-77, 2011

4 Cheung FM, "Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour : clinico-radiologico-pathological correlation and ultrastructural studies" 12 : 319-321, 2006

5 Hesse E, "Oncogenic osteomalacia : exact tumor localization by coregistration of positron emission and computed tomography" 22 : 158-162, 2007

6 Folpe AL, "Most osteomalacia associated mesenchymal tumors are a single histopathologic entity : an analysis of 32 cases and a comprehensive review of the literature" 28 : 1-30, 2004

7 Uramoto N, "Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue" 36 : 104-105, 2009

8 Jadhav S, "Functional imaging in primary tumour-induced osteomalacia : relative performance of FDG PET/CT vs somatostatin receptor-based functional scans : a series of nine patients" 81 : 31-37, 2014

9 Jonsson KB, "Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia" 348 : 1656-1663, 2003

10 Ramon I, "Fibroblast growth factor 23 and its role in phosphate homeostasis" 162 : 1-10, 2009

11 Khosravi A, "Determination of the elimination half-life of fibroblast growth factor-23" 92 : 2374-2377, 2007

12 Duet M, "Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia" 33 : 752-756, 2008

13 Garcia CA, "Bone and In-111 octreotide imaging in oncogenic osteomalacia : a case report" 27 : 582-583, 2002

14 Wild D, "68Ga-DOTANOC : a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5" 32 : 724-, 2005

15 von Falck C, "(68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia" 35 : 1034-, 2008